The U.S. pharmaceutical contract development and manufacturing organization (CDMO) market is on the cusp of notable expansion, driven by several key factors including the increasing prominence of biologics and advanced therapies, a surge in drug development outsourcing, and a rise in clinical trial activities.
According to a recent report from ResearchAndMarkets.com, the market size for U.S. pharmaceutical CDMOs was valued at USD 38.8 billion in 2025. It is expected to grow to USD 65.3 billion by 2033, reflecting a compound annual growth rate (CAGR) of 6.74% during this period.
The growth in this sector is particularly fueled by the demand for specialized services that cater to complex therapeutics. Many pharmaceutical companies currently lack the in-house capabilities required for developing and manufacturing these advanced therapies. CDMOs offer essential infrastructure, regulatory expertise, and innovative platforms that facilitate accelerated development while adhering to FDA standards.
As the approval rates for biologics and biosimilars in the U.S. increase, CDMOs have become vital partners for pharmaceutical firms. Their role is crucial in scaling production capabilities, ensuring supply chain resilience, and enabling quicker market entry for sophisticated, high-value therapeutics.
The report provides a detailed segmentation of the U.S. pharmaceutical CDMO market, analyzing various factors such as type, product, service, workflow, therapeutic area, and end use. This comprehensive analysis aims to forecast revenue growth at global, regional, and national levels, highlighting trends across different sub-segments from 2021 to 2033.
In conclusion, the U.S. pharmaceutical CDMO market stands at a pivotal juncture, with significant growth opportunities arising from the evolving landscape of drug development and the increasing complexity of therapeutic products. As CDMOs adapt to these challenges, they will play a crucial role in shaping the future of the pharmaceutical industry.
